Workshop on phase I study design. Ninth NCI/EORTC New Drug Development Symposium, Amsterdam, March 12, 1996

Annals of Oncology

Volumn 7, Issue 6, 1996, Pages 567-573

  Arbuck, S G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG DEVELOPMENT; DRUG TOXICITY; HUMAN; METHODOLOGY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0029793053     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010672     Document Type: Conference Paper

References (8)

1. Verweij J. Starting dose levels for phase I studies Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1996 13 March 12–15, (Abstr)
2. Smith A.C. Rubinstein L. Koutsoukos A. Evaluation of preclinical toxicity models for phase I clinical trials of anticancer drugs: The NCI experience (1983–1992) Proc AACR 35 1994 459 (Abstr)
3. Connors T.A. Drug development within the EORTC Proceedings of the 9th NCI/EORTC Symposium on New Drugs in Cancer Therapy 9 1996 (Abstr)
4. Kaye S.B. Dose-limiting toxicity: Can we make uniform definitions? Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam, March 12–15 13 1996 (Abstr)
5. Blackwell S. Crawford J. Filgrastim (r-metHuG-CSF) in the chemotherapy setting Morstyn G. Dexter T.M. Filgrastim (r-metHuG-CSF) in Clinical Practice 1994 Marcel Dekker, Inc. New York 114
6. Steward W.P. Phase I studies - alternative endpoints: When is toxicity not appropriate? Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1996 13 March 12–15, (Abstr)
7. Christian M.C. Dose escalation schemes: Are alternatives to Fibonacci useful? Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1996 13 March 12–15, (Abstr)
8. Von Hoff D. Is response in phase I trials a useful predictor for the future clinical activity of a new agent? Proceedings of the 9th NCI-EORTC Symposium on New Drugs in Cancer Therapy, Amsterdam 1996 14 March 12–15, (Abstr)